Size-Selected Platelet Extracellular Vesicles for Inhaled Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhalable formulations for respiratory tract treatments, such as chemically synthesized drugs, biologics, and cell-based therapies, are inconvenient, invasive, costly, and pose side effects, with chemically synthesized drugs and biologics requiring special storage conditions and leading to tolerance issues.
Innovation Solution
A pharmaceutical composition comprising freeze and thaw activated platelet-derived extracellular vesicles, processed by size exclusion chromatography to achieve different particle sizes, which are transformed into inhalers via lyophilization or nebulization, allowing for non-invasive administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemically synthesized drugs, biologics, or cell-based therapies are used for respiratory tract treatment, then therapeutic efficacy is improved, but storage requirements become more stringent and cost increases
Solution Approach 1:
The invention changes the physical and chemical parameters of the therapeutic agent by using platelet-derived extracellular vesicles instead of conventional chemically synthesized drugs or biologics. These vesicles can be stored at room temperature or under less stringent conditions compared to traditional biologics that require cold chain storage, thereby improving ease of manufacture and distribution while maintaining therapeutic efficacy
Solution Approach 2:
The platelet-derived extracellular vesicles are produced from readily available platelet-rich plasma and can be prepared in a single-use format that eliminates the need for complex storage infrastructure. The vesicles are administered directly after preparation through inhalation, reducing storage and distribution costs while maintaining reliable therapeutic effect
2Reliability
If chemically synthesized drugs, biologics, or cell-based therapies are administered via injection, then therapeutic efficacy is improved, but invasiveness increases
Solution Approach 1:
The invention utilizes the respiratory system's natural pneumatic function to deliver therapeutic agents. The platelet-derived extracellular vesicles are aerosolized and inhaled through the lungs, allowing non-invasive administration that bypasses the need for injections while maintaining therapeutic efficacy through direct delivery to respiratory tract tissues
Solution Approach 2:
The platelet-derived extracellular vesicles serve as an intermediary carrier that can be easily aerosolized and delivered via inhalation. These vesicles mediate the transfer of therapeutic benefits from the inhalation route to the target tissues, enabling non-invasive administration while preserving the therapeutic effects traditionally achieved only through invasive injection methods
3Reliability
If biologics or cell-based therapies are used, then therapeutic efficacy is improved, but cost increases
Solution Approach 1:
The platelet-derived extracellular vesicles utilize the body's own platelets as the source material, eliminating the need for expensive external biologic products or cell-based therapies. The vesicles are prepared from the patient's or donor's platelet-rich plasma through a simplified process, significantly reducing production costs while maintaining the therapeutic efficacy associated with biologics
Solution Approach 2:
The invention employs a cost-effective approach by using readily available platelets as the source material instead of expensive biologic products. The extracellular vesicles are produced in a simple, scalable process that can be manufactured at lower cost while providing comparable therapeutic benefits, making the treatment more accessible and affordable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides effective wound healing and inflammation alleviation in respiratory tract tissues with improved storage conditions, reduced side effects, and lower costs, while being easy to use and mass-produce.
Implementation Method 1
subjecting the platelet solution to repeated freeze-thaw cycles to obtain a freeze and thaw activated platelet solution
Implementation Method 2
the freeze and thaw activated platelet-derived extracellular vesicle is processed by size exclusion chromatography (SEC) to have different particle sizes
Implementation Method 3
centrifuging a human whole blood sample to separate a plasma layer and remove leukocytes and erythrocytes, thereby obtaining platelet-rich plasma (PRP)
Data Source
AI summary
The present disclosure provides a pharmaceutical composition including a freeze and thaw activated platelet-derived extracellular vesicle with different sizes, the preparation process thereof and a use of the pharmaceutical composition for promoting wound healing of respiratory tract-related tissues and alleviating inflammation. The pharmaceutical composition of the present disclosure achieves the effect of promoting wound healing of respiratory tract-related tissues and alleviating inflammation through various efficacy experiments.